within Pharmacolibrary.Drugs.ATC.N;

model N02BG06_1
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00045166666666666673,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0715,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0818,
    k12             = 13.2,
    k21             = 13.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N02BG06_1</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Nefopam is a centrally-acting non-opioid analgesic used for the relief of moderate to severe pain. It is unrelated chemically to NSAIDs or opioids and acts by inhibiting the reuptake of serotonin, norepinephrine, and dopamine. Nefopam is used in some countries for acute and chronic pain management but is not approved in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics after single intravenous bolus in healthy adults.</p><h4>References</h4><ol><li><p>Aymard, G, et al., &amp; Diquet, B (2003). Comparative pharmacokinetics and pharmacodynamics of intravenous and oral nefopam in healthy volunteers. <i>Pharmacology &amp; toxicology</i> 92(6) 279–286. DOI:<a href=\"https://doi.org/10.1034/j.1600-0773.2003.920605.x\">10.1034/j.1600-0773.2003.920605.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12787260/\">https://pubmed.ncbi.nlm.nih.gov/12787260</a></p></li><li><p>Djerada, Z, et al., &amp; Malinovsky, JM (2014). Population pharmacokinetics of nefopam in elderly, with or without renal impairment, and its link to treatment response. <i>British journal of clinical pharmacology</i> 77(6) 1027–1038. DOI:<a href=\"https://doi.org/10.1111/bcp.12291\">10.1111/bcp.12291</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24252055/\">https://pubmed.ncbi.nlm.nih.gov/24252055</a></p></li><li><p>Mimoz, O, et al., &amp; Levy, RH (2010). Nefopam pharmacokinetics in patients with end-stage renal disease. <i>Anesthesia and analgesia</i> 111(5) 1146–1153. DOI:<a href=\"https://doi.org/10.1213/ANE.0b013e3181f33488\">10.1213/ANE.0b013e3181f33488</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20971961/\">https://pubmed.ncbi.nlm.nih.gov/20971961</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N02BG06_1;
